Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
This study looks at how well two different combinations of drugs work for treating Crohn's disease. Researchers want to see if these treatments help patients feel better and improve their symptoms.…
High Dietary Inflammatory Index Linked to Increased NAFLD Risk (OR 1.33, CI 1.23-1.44)
Meta-analysis of 262,468 participants shows high Dietary Inflammatory Index (DII) significantly increases risk of NAFLD (OR 1.33, 95% CI: 1.23-1.44, P < 0.00001) and fibrosis (OR 1.36, 95% CI: 1.20-1.…
Researchers studied how certain diets might affect liver health, specifically non-alcoholic fatty liver disease. They found that a diet with high inflammatory potential is connected to a greater risk …